Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
TNF Pharmaceuticals ( (TNFA) ) has provided an announcement.
On June 3, 2025, TNF Pharmaceuticals reconvened its 2025 annual stockholder meeting, initially adjourned from May 20, 2025. During the meeting, shareholders approved an amendment to increase the number of authorized common stock shares from 250 million to 1.25 billion. Additionally, a proposal was approved to allow the board to increase the stated value of Series F and F-1 Convertible Preferred Stock up to $1,125 per share. The meeting also saw the re-election of six directors and the ratification of Stephano Slack LLC as the independent auditor for 2025. These decisions are expected to enhance the company’s capital structure and governance, potentially impacting its market positioning and shareholder value.
More about TNF Pharmaceuticals
TNF Pharmaceuticals, Inc. operates within the pharmaceutical industry, focusing on the development and distribution of pharmaceutical products. The company is involved in the production of various types of stock, including common and preferred stocks, and is engaged in activities related to corporate governance and shareholder meetings.
Average Trading Volume: 2,276,821
Technical Sentiment Signal: Strong Sell
Current Market Cap: $2.32M
For an in-depth examination of TNFA stock, go to TipRanks’ Stock Analysis page.